Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$176.2MCash, Jun 2026
12moCash Runway (est.)
+96%Share Count, 1 Year
Follow TNXP by emailGet an email when TNXP pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TNXP, unsubscribe in one click. Privacy
📣 What TNXP Says Is Next
second half of 2026 · “A Phase 2, open-label, investigator-initiated study in adult kidney transplant patients at Massachusetts General Hospital (MGH) is expected to initiate in the second half of 2026 pending FDA clearance of MGH’s IND application.”
Company press release, Aug 10, 2026 · SEC filing
mid-2027 · “TNX-801 is expected to enter a Phase 1 study in mid-2027 pending FDA clearance of the Investigational New Drug (IND) application.”
Company press release, Aug 10, 2026 · SEC filing
first quarter of 2027 · “The Company expects to deliver investigational product to the Phase 2 clinical study sites in the first quarter of 2027.”
Company press release, Aug 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
TNXP reported $176.2M in cash and short-term investments (as of Jun 30, 2026) and used about $42.6M/quarter in operations, an estimated runway of 12.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:63 · High
Cash runway 12 months +18
ATM program on file since Nov 2025 +15
Shelf registration (S-3, Jun 2025) +10
Share count +96% in a year +20
Recent financing filings on SEC EDGAR:
Dec 29, 2025 · Registered direct / best-efforts offering · 424B5
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TNXP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.